Alliance Pharma completed the acquisition of ScarAway from Perrigo for £14.8m.

Alliance Pharma, a distributor of consumer healthcare brands and prescription medicines, completed the acquisition of ScarAway, a silicone-based scar treatment brand, from Perrigo, a manufacturer of over-the-counter self-care products and supplier of infant formulas for the store brand market, for £14.8m. "I'm delighted to have completed such a strategically important and earnings enhancing acquisition for Alliance which creates our first fully global brand in Kelo-cote and significantly enhances our presence in the largest consumer healthcare market in the world," Peter Butterfield, Alliance Chief Executive Officer.